Biosimilars

Biosimilars

Great Britain – Herzuma® (trastuzumab) 150 mg powder for concentrate for solution for infusion

This medicine is subject to additional monitoring. This will allow quick identification of new safety information. You can help by reporting any side effects you may get. See www.mhra.gov.uk/yellowcard for how to report side effects.

SPC PIL

Northern Ireland – Herzuma® (trastuzumab) 150 mg powder for concentrate for solution for infusion

This medicine is subject to additional monitoring. This will allow quick identification of new safety information. You can help by reporting any side effects you may get. See www.mhra.gov.uk/yellowcard for how to report side effects.

SPC PIL

Great Britain – Herzuma® (trastuzumab) 420 mg powder for concentrate for solution for infusion

This medicine is subject to additional monitoring. This will allow quick identification of new safety information. You can help by reporting any side effects you may get. See www.mhra.gov.uk/yellowcard for how to report side effects.

SPC PIL

Northern Ireland – Herzuma® (trastuzumab) 420 mg powder for concentrate for solution for infusion

This medicine is subject to additional monitoring. This will allow quick identification of new safety information. You can help by reporting any side effects you may get. See www.mhra.gov.uk/yellowcard for how to report side effects.

SPC PIL

Truxima® (rituximab) 100 mg concentrate for solution for infusion

This medicine is subject to additional monitoring. This will allow quick identification of new safety information. You can help by reporting any side effects you may get. See www.mhra.gov.uk/yellowcard for how to report side effects

SPC PIL

Truxima® (rituximab) 500 mg concentrate for solution for infusion

This medicine is subject to additional monitoring. This will allow quick identification of new safety information. You can help by reporting any side effects you may get. See www.mhra.gov.uk/yellowcard for how to report side effects

SPC PIL

Pelmeg® (pegfilgrastim) 6 mg solution for injection in pre-filled syringe

This medicine is subject to additional monitoring. This will allow quick identification of new safety information. You can help by reporting any side effects you may get. See www.mhra.gov.uk/yellowcard for how to report side effects.

SPC PIL

The following websites and documents offer information and resources about biosimilar medicines and/or related disease areas:

Breast Cancer Now: A spotlight on biosimilars

Biosimilars for Lymphoma

Date of preparation: March 2021 UK-BIOS-2100002

Stay connected

Date of preparation: March 2021 UK-BIOS-2100002